Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026)
Bicycle Therapeutics (BCYC) posted Return on Capital Employed of 38.1% for Q1 2026, down 5.44% on a QoQ basis from 36.13% in Q4 2025, and down 931.0% year-over-year from 4.58% in Q1 2025.
Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Bicycle Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 38.1% for Q1 2026.
- Quarterly Return on Capital Employed fell 931.0% year-over-year to 38.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.1% (down 931.0% YoY) and the FY2025 annual result came in at 31.66%, down 206.0% from the prior year.
- Return on Capital Employed was 38.1% for Q1 2026 at Bicycle Therapeutics, down from 36.13% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 17.73% in Q1 2022 and bottomed at 39.79% in Q3 2025.
- A 5-year average of 30.91% and a median of 34.47% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 1509 bps — and 2025, when it sank 1956 bps.
- Bicycle Therapeutics' Return on Capital Employed stood at 32.36% in 2022, then decreased by 7 bps to 34.69% in 2023, then jumped by 33 bps to 23.07% in 2024, then plunged by 57 bps to 36.13% in 2025, then dropped by 5 bps to 38.1% in 2026.
- Business Quant data shows BCYC's Return on Capital Employed at 38.1% in Q1 2026, 36.13% in Q4 2025, and 39.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -38.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.10% |
| Dec 31, 2025 | -36.13% |
| Sep 30, 2025 | -39.79% |
| Jun 30, 2025 | -36.93% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -23.07% |
| Sep 30, 2024 | -20.24% |
| Jun 30, 2024 | -25.03% |
| Mar 31, 2024 | -34.47% |
| Dec 31, 2023 | -34.69% |
| Sep 30, 2023 | -35.23% |
| Jun 30, 2023 | -39.78% |
| Mar 31, 2023 | -35.74% |
| Dec 31, 2022 | -32.36% |
| Sep 30, 2022 | -26.29% |
| Jun 30, 2022 | -21.16% |
| Mar 31, 2022 | -17.73% |
| Dec 31, 2021 | -19.06% |
| Sep 30, 2021 | -28.93% |
| Jun 30, 2021 | -30.26% |